Omkar Spl.Chem.

- No mention of any new fundraising through equity in the provided transcript. - Current debt as of September 30, 2016, stands at Rs. 243 crores (including Rs. 27 crores promoter funding). - The company has repaid Rs. 12 crores term loan in H1 FY17 and expects to reduce outside debt by a similar amount in H2 FY17. - A line of credit sanction from banks is in final approval phase, expected to be released within 1 to 1.5 months to meet working capital needs. - Promoters have extended Rs. 27 crores loan at a lower interest rate to replace higher-cost NBFC funding, which will help reduce interest cost. - No explicit statement regarding fresh fundraising through debt or equity; focus is on optimizing existing credit lines and replacing high-cost funds.

- Current CAPEX mainly for debottlenecking, replacing old equipment, and upgrading API manufacturing facilities to WHO GMP standards (Page 11). - Unit 5, a new manufacturing unit for veterinary APIs, is under construction with expected commissioning by Q4 FY17; initial capacity utilization starts at 30-40%, ramping up to 80% by FY19 (Pages 8-10). - Post-commissioning of Unit 5 and ongoing CAPEX, the company expects doubling of turnover by mid-FY20 (Page 9). - CAPEX related to upgrading other facilities (LASA, Urdhwa) to support regulatory market supply and higher margins (Page 11). - No major new CAPEX expected beyond current projects in the next 2-3 years; focus is on expansion and utilization of existing/upgraded capacities (Page 11). - Total WIP as of September 2016 is ₹140 crores, primarily related to Unit 5 and API upgrades; expected capitalization by March 2017 if commissioning completes on time (Page 11).

- Expect turnover to double by mid-FY20 due to full capacity utilization of new unit 5. - Capacity utilization for new unit 5 will ramp up gradually: 30-40% initially, 55-60% next, then 70-75%, reaching 80% by FY19. - Planned growth rate for both parent company and LASA super generics is 15%-20% annually. - Growth driven by: * Launch of new molecules with customer approvals. * Scale-up of existing products. - Export growth momentum sustained, with ongoing focus on European markets (Germany, France, Spain, Belgium). - Business segments (API and specialty chemicals) expected to maintain steady contributions, with APIs growing to 15%-20% of revenue. - Order flow expected to support expansion without issues. - Overall, conservative estimates indicate steady growth aligned with capacity expansions and market demand.

- Company expects revenue to potentially double by mid-FY20 with full capacity utilization of new Unit 5. - Growth rate projected conservatively at 15%-20% annually for both parent company and LASA Super Generics. - EBITDA margin improvements noted with 20% margin in H1 FY17; continuing focus on operating efficiencies and productivity. - PAT grew by 31% YoY in H1 FY17, indicating improving profitability. - New molecule launches and scale-up of existing products are main growth drivers. - Expansion of exports mainly to European regulatory markets expected to continue. - CAPEX largely completed, mainly for debottlenecking and facility upgrades to WHO GMP standards, supporting growth. - Demerger and depledging processes expected to unlock shareholder value and improve financial flexibility. - No major capex expected beyond current projects, implying stable margins. - Overall strong growth momentum and controlled working capital indicating sustainable profit growth.

- The management expects strong order flow driven by new molecule launches and scale-up of existing products. - Orders are primarily from regulatory markets, especially Europe (Germany, France, Spain, Belgium). - Current capacity utilization for existing units is high (75%-87%), with Unit 5 expected to commence production in Q4 FY17. - Unit 5 will gradually ramp up to full capacity by FY19, potentially doubling turnover by mid-FY20. - Growth momentum continues in Q3 FY17 with stable export orders; Q4 expected to see fewer orders due to holidays but with new orders anticipated from January. - Orderbook outlook is positive and the company does not foresee issues in meeting order demand with enhanced capacity. - The company’s export orders are mostly billed in US dollars (~90%) with some in euros.